Inhibition of tumor growth with a vaccine based on xenogeneic homologous fibroblast growth factor receptor-1 in mice

Qiu ming He, Yu quan Wei, Ling Tian, Xia Zhao, Jing mei Su, Li Yang, You Lu, Bin Kan, Yanyan Lou, Mei juan Huang, Fei Xiao, Ji yan Liu, Bing Hu, Feng Luo, Yu Jiang, Yan jun Wen, Hong xin Deng, Jiong Li, Tin Niu, Jin liang Yang

Research output: Contribution to journalArticle

72 Citations (Scopus)

Abstract

Angiogenesis is important for the growth of solid tumors. The breaking of the immune tolerance against the molecule associated with angiogenesis should be a useful approach for cancer therapy. However, the immunity to self-molecules is difficult to elicit by a vaccine based on autologous or syngeneic molecules due to immune tolerance. Basic fibroblast growth factor (bFGF) is a specific and potent angiogenic factor implicated in tumor growth. The biological activity of bFGF is mediated through interaction with its high-affinity receptor, fibroblast growth factor receptor-1 (FGFR-1). In this study, we selected Xenopus FGFR-1 as a model antigen by the breaking of immune tolerance to explore the feasibility of cancer therapy in murine tumor models. We show here that vaccination with Xenopus FGFR-1 (pxFR1) is effective at antitumor immunity in three murine models. FGFR-1-specific autoantibodies in sera of pxFR1-immunized mice could be found in Western blotting analysis. The purified immunoglobulins were effective at the inhibition of endothelial cell proliferation in vitro and at the antitumor activity in vivo. The antitumor activity and production of FGFR-1-specific autoantibodies could be abrogated by depletion of CD4+ T lymphocytes. Histological examination revealed that the autoantibody was deposited on the endothelial cells within tumor tissues from pxFR1-immunized mice, and intratumoral angiogenesis was significantly suppressed. Furthermore, the inhibition of angiogenesis could also be found in alginate-encapsulate tumor cell assay. These observations may provide a new vaccine strategy for cancer therapy through the induction of autoimmunity against FGFR-1 associated with angiogenesis in a cross-reaction.

Original languageEnglish (US)
Pages (from-to)21831-21836
Number of pages6
JournalJournal of Biological Chemistry
Volume278
Issue number24
DOIs
StatePublished - Jun 13 2003
Externally publishedYes

Fingerprint

Receptor, Fibroblast Growth Factor, Type 1
Tumors
Vaccines
Immune Tolerance
Growth
Autoantibodies
Neoplasms
Endothelial cells
Fibroblast Growth Factor 2
Molecules
Xenopus
Immunity
Endothelial Cells
Cancer Vaccines
T-cells
Angiogenesis Inducing Agents
Cell proliferation
Bioactivity
Cross Reactions
Mouse Fgfr1 protein

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology
  • Cell Biology

Cite this

Inhibition of tumor growth with a vaccine based on xenogeneic homologous fibroblast growth factor receptor-1 in mice. / He, Qiu ming; Wei, Yu quan; Tian, Ling; Zhao, Xia; Su, Jing mei; Yang, Li; Lu, You; Kan, Bin; Lou, Yanyan; Huang, Mei juan; Xiao, Fei; Liu, Ji yan; Hu, Bing; Luo, Feng; Jiang, Yu; Wen, Yan jun; Deng, Hong xin; Li, Jiong; Niu, Tin; Yang, Jin liang.

In: Journal of Biological Chemistry, Vol. 278, No. 24, 13.06.2003, p. 21831-21836.

Research output: Contribution to journalArticle

He, QM, Wei, YQ, Tian, L, Zhao, X, Su, JM, Yang, L, Lu, Y, Kan, B, Lou, Y, Huang, MJ, Xiao, F, Liu, JY, Hu, B, Luo, F, Jiang, Y, Wen, YJ, Deng, HX, Li, J, Niu, T & Yang, JL 2003, 'Inhibition of tumor growth with a vaccine based on xenogeneic homologous fibroblast growth factor receptor-1 in mice', Journal of Biological Chemistry, vol. 278, no. 24, pp. 21831-21836. https://doi.org/10.1074/jbc.M300880200
He, Qiu ming ; Wei, Yu quan ; Tian, Ling ; Zhao, Xia ; Su, Jing mei ; Yang, Li ; Lu, You ; Kan, Bin ; Lou, Yanyan ; Huang, Mei juan ; Xiao, Fei ; Liu, Ji yan ; Hu, Bing ; Luo, Feng ; Jiang, Yu ; Wen, Yan jun ; Deng, Hong xin ; Li, Jiong ; Niu, Tin ; Yang, Jin liang. / Inhibition of tumor growth with a vaccine based on xenogeneic homologous fibroblast growth factor receptor-1 in mice. In: Journal of Biological Chemistry. 2003 ; Vol. 278, No. 24. pp. 21831-21836.
@article{f17ab62d4a9a4821abf38552e562ce6e,
title = "Inhibition of tumor growth with a vaccine based on xenogeneic homologous fibroblast growth factor receptor-1 in mice",
abstract = "Angiogenesis is important for the growth of solid tumors. The breaking of the immune tolerance against the molecule associated with angiogenesis should be a useful approach for cancer therapy. However, the immunity to self-molecules is difficult to elicit by a vaccine based on autologous or syngeneic molecules due to immune tolerance. Basic fibroblast growth factor (bFGF) is a specific and potent angiogenic factor implicated in tumor growth. The biological activity of bFGF is mediated through interaction with its high-affinity receptor, fibroblast growth factor receptor-1 (FGFR-1). In this study, we selected Xenopus FGFR-1 as a model antigen by the breaking of immune tolerance to explore the feasibility of cancer therapy in murine tumor models. We show here that vaccination with Xenopus FGFR-1 (pxFR1) is effective at antitumor immunity in three murine models. FGFR-1-specific autoantibodies in sera of pxFR1-immunized mice could be found in Western blotting analysis. The purified immunoglobulins were effective at the inhibition of endothelial cell proliferation in vitro and at the antitumor activity in vivo. The antitumor activity and production of FGFR-1-specific autoantibodies could be abrogated by depletion of CD4+ T lymphocytes. Histological examination revealed that the autoantibody was deposited on the endothelial cells within tumor tissues from pxFR1-immunized mice, and intratumoral angiogenesis was significantly suppressed. Furthermore, the inhibition of angiogenesis could also be found in alginate-encapsulate tumor cell assay. These observations may provide a new vaccine strategy for cancer therapy through the induction of autoimmunity against FGFR-1 associated with angiogenesis in a cross-reaction.",
author = "He, {Qiu ming} and Wei, {Yu quan} and Ling Tian and Xia Zhao and Su, {Jing mei} and Li Yang and You Lu and Bin Kan and Yanyan Lou and Huang, {Mei juan} and Fei Xiao and Liu, {Ji yan} and Bing Hu and Feng Luo and Yu Jiang and Wen, {Yan jun} and Deng, {Hong xin} and Jiong Li and Tin Niu and Yang, {Jin liang}",
year = "2003",
month = "6",
day = "13",
doi = "10.1074/jbc.M300880200",
language = "English (US)",
volume = "278",
pages = "21831--21836",
journal = "Journal of Biological Chemistry",
issn = "0021-9258",
publisher = "American Society for Biochemistry and Molecular Biology Inc.",
number = "24",

}

TY - JOUR

T1 - Inhibition of tumor growth with a vaccine based on xenogeneic homologous fibroblast growth factor receptor-1 in mice

AU - He, Qiu ming

AU - Wei, Yu quan

AU - Tian, Ling

AU - Zhao, Xia

AU - Su, Jing mei

AU - Yang, Li

AU - Lu, You

AU - Kan, Bin

AU - Lou, Yanyan

AU - Huang, Mei juan

AU - Xiao, Fei

AU - Liu, Ji yan

AU - Hu, Bing

AU - Luo, Feng

AU - Jiang, Yu

AU - Wen, Yan jun

AU - Deng, Hong xin

AU - Li, Jiong

AU - Niu, Tin

AU - Yang, Jin liang

PY - 2003/6/13

Y1 - 2003/6/13

N2 - Angiogenesis is important for the growth of solid tumors. The breaking of the immune tolerance against the molecule associated with angiogenesis should be a useful approach for cancer therapy. However, the immunity to self-molecules is difficult to elicit by a vaccine based on autologous or syngeneic molecules due to immune tolerance. Basic fibroblast growth factor (bFGF) is a specific and potent angiogenic factor implicated in tumor growth. The biological activity of bFGF is mediated through interaction with its high-affinity receptor, fibroblast growth factor receptor-1 (FGFR-1). In this study, we selected Xenopus FGFR-1 as a model antigen by the breaking of immune tolerance to explore the feasibility of cancer therapy in murine tumor models. We show here that vaccination with Xenopus FGFR-1 (pxFR1) is effective at antitumor immunity in three murine models. FGFR-1-specific autoantibodies in sera of pxFR1-immunized mice could be found in Western blotting analysis. The purified immunoglobulins were effective at the inhibition of endothelial cell proliferation in vitro and at the antitumor activity in vivo. The antitumor activity and production of FGFR-1-specific autoantibodies could be abrogated by depletion of CD4+ T lymphocytes. Histological examination revealed that the autoantibody was deposited on the endothelial cells within tumor tissues from pxFR1-immunized mice, and intratumoral angiogenesis was significantly suppressed. Furthermore, the inhibition of angiogenesis could also be found in alginate-encapsulate tumor cell assay. These observations may provide a new vaccine strategy for cancer therapy through the induction of autoimmunity against FGFR-1 associated with angiogenesis in a cross-reaction.

AB - Angiogenesis is important for the growth of solid tumors. The breaking of the immune tolerance against the molecule associated with angiogenesis should be a useful approach for cancer therapy. However, the immunity to self-molecules is difficult to elicit by a vaccine based on autologous or syngeneic molecules due to immune tolerance. Basic fibroblast growth factor (bFGF) is a specific and potent angiogenic factor implicated in tumor growth. The biological activity of bFGF is mediated through interaction with its high-affinity receptor, fibroblast growth factor receptor-1 (FGFR-1). In this study, we selected Xenopus FGFR-1 as a model antigen by the breaking of immune tolerance to explore the feasibility of cancer therapy in murine tumor models. We show here that vaccination with Xenopus FGFR-1 (pxFR1) is effective at antitumor immunity in three murine models. FGFR-1-specific autoantibodies in sera of pxFR1-immunized mice could be found in Western blotting analysis. The purified immunoglobulins were effective at the inhibition of endothelial cell proliferation in vitro and at the antitumor activity in vivo. The antitumor activity and production of FGFR-1-specific autoantibodies could be abrogated by depletion of CD4+ T lymphocytes. Histological examination revealed that the autoantibody was deposited on the endothelial cells within tumor tissues from pxFR1-immunized mice, and intratumoral angiogenesis was significantly suppressed. Furthermore, the inhibition of angiogenesis could also be found in alginate-encapsulate tumor cell assay. These observations may provide a new vaccine strategy for cancer therapy through the induction of autoimmunity against FGFR-1 associated with angiogenesis in a cross-reaction.

UR - http://www.scopus.com/inward/record.url?scp=0038498050&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038498050&partnerID=8YFLogxK

U2 - 10.1074/jbc.M300880200

DO - 10.1074/jbc.M300880200

M3 - Article

C2 - 12651849

AN - SCOPUS:0038498050

VL - 278

SP - 21831

EP - 21836

JO - Journal of Biological Chemistry

JF - Journal of Biological Chemistry

SN - 0021-9258

IS - 24

ER -